Quantcast

Latest Rhinitis Stories

2008-07-18 12:01:14

Schering-Plough has announced that Schering-Plough KK, the company's country operation in Japan, has received marketing approval for Nasonex nasal spray 50mcg for the treatment of allergic rhinitis in adult patients. Schering-Plough's Nasonex is an intranasal steroid that significantly improves nasal allergy symptoms when taken once each day. Nasonex is said to be the first intranasal steroid to be approved in Japan for once-daily administration. Nasonex is currently approved in over 100...

2008-07-17 12:01:18

KENILWORTH, N.J., July 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for NASONEX(R) (mometasone furoate monohydrate) Nasal Spray 50mcg* for the treatment of allergic rhinitis in adult patients.(1) NASONEX is an intranasal steroid that significantly improves nasal allergy symptoms when taken once each day. NASONEX is the first intranasal steroid to be approved in...

2008-07-01 00:14:24

By Madhavi Rajadhyaksha MUMBAI: If you've been blaming your allergic cough, running nose and itchy skin on flowering trees or neighbourhood pets, it's time to do a rethink. Insects, particularly mosquitoes, cockroaches and dust mites, are to blame for nearly 50% of the allergies in India. And food - especially peanuts, chocolates and legumes - is the other big culprit. This is what a Mumbai allergy specialist found after he set out to map the "desi" allergy index. "Since we are a...

2008-06-27 03:02:32

Greer has completed enrollment for its pivotal Phase III clinical trial designed to study the efficacy of sublingual-oral immunotherapy as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen. Between March and June 2008, 556 patients were screened for the randomized, double-blind, placebo-controlled trial, of which 430 were enrolled. The participants will be observed at 31 clinical sites across the country. The trial will last approximately seven...

2008-06-26 12:03:21

Greer, a leading developer and provider of allergy immunotherapy products and services, has completed enrollment for its pivotal Phase III clinical trial designed to study the efficacy of sublingual-oral immunotherapy (SLIT) as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen. It is estimated that 30 million Americans are allergic to short ragweed pollen, making it one of the most common allergens. Between March and June, 556 patients were screened...

2008-06-25 06:03:22

Morria Biopharmaceuticals has initiated a Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis. The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes Rhinocort as the steroid comparator arm. The study is expected to be completed by the end of third quarter 2008. The study is designed to evaluate the safety, tolerability, and efficacy of intranasal MRX-4 in allergic rhinitis (AR) patients outside...

2008-06-22 09:00:30

By Ted Gregory, Chicago Tribune Jun. 22--Joseph Leija is a soft-spoken 78-year-old allergist who has been practicing medicine for 50 years. But when he makes his way to the rooftop of a suburban medical building, he becomes something more: Dr. Pollen. Leija is the sole provider of official pollen counts in Illinois, a critical role considering that an estimated 60 million people are suffering from allergies in the U.S. And that number is growing. An assortment of news outlets,...

2008-06-17 12:00:09

MILWAUKEE, Wisconsin, June 17 /PRNewswire/ -- - First World Allergy Report Calls for Urgent Worldwide Collaboration to Tackle Global Increase in Allergies and Allergic Diseases The World Allergy Organization (WAO) will publish its first Report on the extent of allergy and chronic respiratory diseases worldwide on the 18 June 2008 and has called for immediate collaboration to tackle the current escalation in allergy cases. In the last 20-30 years, the prevalence of allergic diseases has...

2008-06-02 15:01:11

CORAL SPRINGS, Fla., June 2 /PRNewswire/ -- Boca Pharmacal, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pamlab's Palgic(R) 4mg Tablet (Carbinoxamine Maleate 4 mg Tablet). The Company plans to launch its product immediately. Carbinoxamine Maleate 4mg Tablet is indicated to treat seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic...

2008-04-22 09:01:16

Sepracor Inc. (Nasdaq: SEPR) announced today the launch of "My Allergies in America" (www.myallergiesinamerica.com), a comprehensive resource for physicians and consumers based on the two-part, landmark "Allergies in America" survey of adults, adolescents and children with allergic rhinitis. The survey, endorsed by the American College of Allergy, Asthma and Immunology (ACAAI), showed that allergies, which affect about 40 million people in the United States, including up to 40 percent...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related